Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)
Blood (2020) 136 (Supplement 1): 37–38.
Currently there are no citedby results. Try again later.
